Background/Aims: To delineate the relationship of polycystic ovary syndrome (PCOS), obesity, and hyperandrogenism (HA) with glucose and insulin dynamics in adolescents across a broad body mass index (BMI). Methods: Seventy-four PCOS subjects (aged 16 years) and 82 controls (aged 16 years) were evaluated by an oral glucose tolerance test. Subjects were categorized by BMI: normal weight (21 ± 0.4), overweight/ obesity (OO; 33 ± 1.0), and severe obesity (SO; 48 ± 1.4). Indices of glucose and insulin dynamics were determined. Multiple linear regression analysis was used to evaluate the contribution of PCOS, HA, and BMI to these indices. Results: BMI was significantly associated with systolic and diastolic blood pressure and insulin resistance. A significant interaction between BMI and PCOS and indices of post-glucose load was observed. The mean difference in peak glucose, early glucose response, area under the curve for glucose, and glucose effectiveness (SgI o ) between PCOS and control subjects was significantly different between OO and SO. In PCOS subjects, testosterone was positively associated with BMI, fasting insulin, early insulin response, and diastolic blood pressure, and negatively associated with SgI o . Conclusions: Abnormal glucose dynamics in adolescents with PCOS is mainly due to SO. The combination of PCOS and SO has a synergistic effect on glucose dynamics when compared to all other groups.
Alterations in Glucose Effectiveness

Introduction
Polycystic ovary syndrome (PCOS) affects 6-15% of reproductive-age women [1] and accounts for 72-84% of hyperandrogenism (HA) in women [2, 3] . In adolescents, PCOS is associated with a 50% reduction in insulin sensitivity (IS) [4, 5] and a higher rate of the metabolic syndrome (10%) than in controls (1.7%) [6] . Similarly, insulin resistance (IR) and a greater glucose area under the curve (G AUC ) are seen in obese adolescents with PCOS when compared to their lean counterparts [7, 8] .
The origin of metabolic dysfunction in PCOS subjects is still being delineated. HA, obesity, and IR have all been implicated in this role. HA may confer IR and metabolic inflammation [9, 10] , and the odds of having metabolic syndrome are almost 4 times greater for every quartile increase in testosterone adjusting for BMI and IR [11] . Even lean PCOS subjects are at an elevated risk of metabolic disease compared with lean controls [9, 12] . This relationship becomes more complicated in obese PCOS subjects as obesity seems to be the major factor that leads to the development of the metabolic syndrome in obese PCOS subjects rather than HA subjects [13] . In fact, obesity is strongly associated with the metabolic syndrome in adolescents independent of their PCOS diagnosis [14] . A recent study further demonstrated that the risk of type 2 diabetes mellitus (T2DM) in women with PCOS is mainly attributable to their overweight/obesity status and that weight gain during early adulthood significantly increased the risk of developing abnormal glucose metabolism [15] .
The aim of this study was to examine adolescents and young women with PCOS over a wide range of body mass indices (BMI) in order to refine our understanding of the relationship of PCOS and BMI with glucose and insulin dynamics assessed by an oral glucose tolerance test (OGTT) using validated indices of glucose and insulin action. The overall goal is to explore these relationships as well as to evaluate the presence of an independent contribution of PCOS status or BMI toward the development of metabolic disease.
Materials and Methods
Subjects
We studied an ethnically diverse group of 156 adolescents and young women with and without PCOS who were recruited between January 2004 and May 2014. PCOS and control subjects were recruited from pediatric endocrinology, bariatric, and adolescent clinics and practices at Columbia University Medical Center (CUMC) as well as by posted flyers, social media, and Listserv postings. PCOS subjects and controls (13-22 years old) were at least 2 years after menarche. PCOS was diagnosed using the NIH criteria [16] in subjects who were biochemically euthyroid and without biochemical evidence of congenital adrenal hyperplasia [17] . Exclusion criteria included the use of medications known to affect hormone, lipid, or insulin levels at the time of enrollment. Controls had regular menses and absence of clinical (hirsutism) or biochemical HA (normal testosterone levels). Seventy-four subjects with PCOS aged 16 ± 0.2 years (BMI 17-64) and 82 controls aged 16 ± 0.1 years (BMI 18-56) were divided into 6 groups based on their BMI, because data have shown that the more severe forms of obesity are associated with greater risks for complications: (1) normal-weight PCOS subjects (NW-PCOS) and controls (NW-C): BMI <25; (2) overweight/obese PCOS subjects (OO-PCOS) and controls (OO-C): BMI 25 to <40; (3) severely obese PCOS subjects (SO-PCOS) and controls (SO-C): BMI ≥40 [18] .
Informed consent was obtained from a legal guardian of each subject aged <18 years and from subjects ≥18 years. The protocols were approved by the Institutional Review Board of CUMC.
Biochemical Analysis
Basal levels of glucose (G 0 ), insulin (I 0 ), testosterone, and HbA 1c were measured after an overnight fast. Glucose was assayed by the glucose hexokinase method. Insulin was measured via chemiluminescence, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were assessed by electrochemiluminescent assay and testosterone by high-performance liquid chromatography with tandem mass spectrometry (Esoterix, Inc., Calabasas Hills, CA, USA). Glucose and HbA 1c analyses were performed at the laboratory of New York Presbyterian Hospital.
Assessment of IS, Insulin Secretion, β-Cell Function, and Glucose Effectiveness
A 75-g 2-h OGTT was performed after an 8-h overnight fast [8] . Sixty-seven controls (11 NW-C, 17 OO-C, and 39 SO-C) and 56 PCOS subjects (19 NW-PCOS, 16 OO-PCOS, and 21 SO-PCOS) completed the OGTT.
IR/IS were estimated by (1) the homeostasis model (HOMA-IR) and (2) the Matsuda index/whole-body IS index (ISI) [8] .
Fasting and post-glucose load were estimated by (1) G 0 and I 0 ; (2) early incremental glucose response (change in glucose levels from 0 to 30 min, ΔG); and (3) total G AUC integrated glucose response to an oral glucose load during 120 min by the trapezoidal method [19] ; (4) time to peak for glucose (min) was defined as the time between the start of the OGTT to the highest glucose levels recorded (Time G ); and (5) peak glucose levels (mg/dL) were defined as the highest glucose levels during the OGTT (Peak G ).
Insulin secretion was estimated by (1) early incremental insulin response (change in insulin levels from 0 to 30 min, ΔI); (2) I AUC integrated insulin response to an oral glucose load during 120 min using the trapezoidal method; (3) time to peak for insulin was defined as the time from the start of the OGTT to the highest insulin levels recorded (Time I ); and (4) peak insulin levels (µUI/mL) were defined as the highest insulin levels during the OGTT (Peak I ).
β-cell function was estimated by (1) the disposition index (DI 0 ) relationship between IS and first-phase insulin secretion; and (2) the Insulin Secretion Sensitivity Index-2 (ISSI-2), the relationship between whole-body IS and I AUC and G AUC [20] .
Glucose effectiveness (SgI o ) determines the capacity of glucose to enhance its own cellular uptake and to suppress endogenous glucose production, as formulated by Nagasaka et al. [21] : E PPG without insulin and Sg 2hPG PPG -without insulin and with Sg 2hPG 120 ,
where PPG = post-loading plasma glucose, Sg = glucose effectiveness, 2hPG = 2-h post-glucose PG, and 2hPG E = expected 2hPG. "PPG-without insulin and Sg" was calculated using: Data Analysis Continuous data were presented as means ± SD. Student t tests were used to compare the means of the continuous variables between the PCOS and control groups. Of note, subjects diagnosed with diabetes were excluded from the analysis (n = 1 PCOS subject). In PCOS subjects, relationships between testosterone levels and indices of glucose and insulin dynamics were evaluated by bivariate analysis. For continuous outcomes, multiple linear regression models were fitted to compare the PCOS and control groups adjusting for BMI as categorical variable (NW, OO, and SO). We first tested the interaction between PCOS status and BMI, then removed the interaction when the interaction was found to be not significant. Parameter estimates from the multiple regression model were reported as well as SE, p value, and 95% confidence intervals. With a sample size of 74 PCOS subjects and 82 controls, the study had 80% power and 5% two-tailed α level to detect a 0.45 standardized difference between the groups. Statistical analyses were performed using JMP IN version 7.0.2 software and SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Clinical Characteristics
The clinical and metabolic characteristics of PCOS subjects and healthy controls are presented in Table 1 . PCOS and control subjects did not differ significantly in age, BMI, age of menarche, and years after menarche. Of the PCOS subjects, 35% were Caucasian, 43% Hispanic, 13% Asian American, 4% African American, and 4% were multiracial or other. Of the controls, 37% were Caucasian, 35% Hispanic, 10% African American, 13% Asian American, and 4% other. Ethnicity did not impact age of menarche (p > 0.1), BMI (p > 0.7), PCOS status (p > 0.6), testosterone levels (p > 0.4), or any of the glucose or insulin indices described below (p > 0.5). Similarly, no differences were seen in blood pressure, G 0 , I 0 , HbA 1c , LH, and FSH levels between PCOS and control subjects. As expected, all PCOS subjects as a group exhibited higher serum testosterone when compared to all controls as a group (p < 0.001).
Of the PCOS subjects, 4% (3 of 74) had glucose dysfunction including impaired fasting glucose (IFG) (2.7%) and diabetes (1.3%). Similar to PCOS subjects, 3% of the controls had IFG (3 of 82) but none had diabetes. Impaired glucose tolerance (IGT) occurred in 15% of PCOS subjects and 1.4% of controls (p < 0.003). Time I occurred, on average, 12 min later in SO-PCOS subjects when compared to NW-PCOS subjects and 13 min later than in SO-C. Time G occurred, on average, 5 min later in SO-PCOS subjects when compared to NW-PCOS subjects and 7 min later than in SO-C (p = ns) (Fig. 1) . In all PCOS subjects, higher testosterone levels were associated with higher BMI (p = 0.0141), I 0 (p = 0.018), ΔI (p = 0.0083), HOMA-IR (p = 0.036), and diastolic blood pressure (DBP) (p = 0.015), and with lower SgI o (p = 0.048). Based on multiple linear regression analyses, ΔI (p = 0.005) and DBP (p = 0.004) were significantly related to testosterone levels independent of BMI. Table 2 shows the results from multivariable general linear models. Severe obesity was associated with higher systolic blood pressure (difference in means, 11.73 ± 2.54 mm Hg, p < 0.001, and 6.29 ± 2.87 mm Hg, p = 0.031) and DBP (difference in means, 10.47 ± 2.09 mm Hg, p < 0.0001, and 5.55 ± 2.39 mm Hg, p < 0.022) when compared to NW-PCOS and NW-C and OO-PCOS and OO-C subjects, respectively. PCOS status did not affect blood pressure. Table 2 shows the results from multivariable general linear models. As expected, SO status was associated with higher HOMA-IR (difference in means, 2.27 ± 0.67, p = 0.001) when compared to NW-PCOS and NW-C subjects and lower ISI (difference in means, 6.63 ± 2.22, p = 0.003) when compared to NW-PCOS subjects and NW-C. PCOS status did not affect indices of IS/IR. Table 3 shows the results from multivariable general linear models. As expected, NW-PCOS and OO-PCOS subjects had a lower risk of having abnormal post-glucose load indices determined by an OGTT than SO-PCOS subjects. Whereas PCOS status was found to be a significant predictor of Peak G , ΔG, and G AUC , the interaction between the presence of PCOS and BMI was statistically significant. Thus, the mean difference in Peak G , ΔG, and G AUC between PCOS and controls was significantly different between OO and SO subjects.
BMI Had a Significant Impact on Blood Pressure
BMI Had a Significant Impact on Indices of IS/IR
BMI and PCOS Status Had a Significant Impact on Indices of Post-Glucose Load
NW subjects had lower I AUC when compared to SO subjects independent of their PCOS status (difference in means, 122.54 ± 61.34, p = 0.048). Similarly, PCOS status was associated with higher I AUC (difference in means, 103.94 ± 51.50, p = 0.046) independently of BMI status. On average, neither PCOS nor BMI independently or together significantly impacted ΔI, DI, and ISSI-2 indices (data not shown). Figure 2 shows the average and SE differences across all BMI categories in both PCOS and control subjects for the indices of Peak G , ΔG, G AUC , and I AUC , although the multivariable analyses described in Table 3 represent the statistical differences between individual categories. Figure 3 shows the results from multivariable general linear models. For each unit increase in BMI, SgI o decreased on average by 0.09 for both the PCOS and control group (p < 0.0001). That relationship is exacerbated in the SO-PCOS and SO-C groups in which SgI o decreased on Interestingly, PCOS status had a significant relationship with SgI o when the BMI was >36.76. The combination of PCOS and a BMI >36.76 explained 88% of the variance in SgI o (r 2 = 0.88; p < 0.0001). This hyperbolic relationship demonstrated that SgI o was significantly lower in PCOS subjects as compared to controls when the BMI was >36.76 consistent with the premise of declining SgI o in SO-PCOS subjects.
BMI and PCOS Status Had a Significant Impact on Glucose Effectiveness
Discussion
In this relatively large, ethnically diverse group of adolescents and young adults with and without PCOS who span a wide range of BMIs, the interaction between SO and PCOS together is associated with impaired glucose dynamics, specifically higher post-load glucose levels (Peak G , ΔG, and G AUC ) and decreased SgI o . This study suggests that SO-PCOS subjects are metabolically different than OO-PCOS subjects when compared to OO-C and SO-C and proposes that SO-PCOS adolescents and young adults are in a unique risk group for the development of abnormalities in glucose and insulin dynamics.
Several studies have tried to address whether PCOS or HA are independent risks factor for developing metabolic disease [10, 11, 22] , or whether this is simply a synergistic effect between PCOS-HA and BMI [23, 24] , or even if the risk is only related to obesity.
In our study, the presence of PCOS was associated with higher I AUC , an index of IR and insulin response to a glucose load. This increase in insulin concentrations after glucose load seen in PCOS subjects may be due to an increase of insulin secretion by the pancreas or a delay in insulin degradation. Similar findings have been seen in nonobese subjects with PCOS, again suggesting that PCOS is an independent risk factor for the development of metabolic disease [25] . To further support this hypothesis, when PCOS subjects were analyzed separately, higher testosterone levels were associated with an increased insulin release during the first 30 min of an OGTT (ΔI) independently of their BMI, suggesting that HA can be associated with IR.
Higher testosterone levels in PCOS subjects were also associated with elevated DBP. The effects of androgen level on blood pressure have been controversial [26] , but a recent study has also suggested that elevated testosterone levels in a group of young women with PCOS is correlated with DBP independent of age, IR, obesity, and dyslipidemia [27] .
In our study, BMI had a significant association with indices of insulin action, specifically HOMA-IR and ISI, in addition to an effect on blood pressure. This finding supports the notion that BMI status likely plays a major role in risk for metabolic disease in PCOS. Similar findings have been supported by other studies in which only obese women with PCOS are at increased risk of T2DM [23, 28, 29] .
Abnormal glucose metabolism in this relatively large ethnically diverse group of adolescents and young adults is mainly associated with SO and PCOS status. Thus, the significant interaction between the presence of PCOS and BMI is consistent with the notion that the risk of T2DM in PCOS is mainly attributable to being SO and NW-PCOS subjects are not at increased risk. Our findings do confirm that whereas PCOS is generally associated with an increased risk of T2DM development, the excess risk is largely confined to SO women [23] .
The interaction of SO and PCOS leads to an increase in post-load glucose levels, specifically Peak G , ΔG, and G AUC . In addition, SO was associated with a later insulin peak in response to an OGTT when compared to other PCOS groups. SO-PCOS subjects also have a decreased capacity for glucose to enhance its own cellular uptake and to suppress endogenous glucose production, as determined by Normal weight (NW), BMI <25; overweight/obese (OO), BMI 25 to <40; severely obese (SO), BMI ≥40. Parameter estimates from the multiple regression model are reported as SE, p value, and 95% confidence intervals (CI). BMI, body mass index; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; Peak G , peak glucose levels; ΔG, early incremental glucose response; G AUC , total area under the curve for glucose; I AUC , total area under the curve for insulin. Post-meal indices of carbohydrate metabolism in polycystic ovary syndrome (PCOS) and control subjects divided into 6 groups based on their body mass index (BMI): normal-weight PCOS subjects (NW-PCOS) and controls (NW-C): BMI <25; overweight/obese PCOS subjects (OO-PCOS) and controls (OO-C): BMI 25 to <40; severely obese PCOS subjects (SO-PCOS) and controls (SO-C): BMI ≥40. All data are presented as mean ± SE for indices of peak glucose levels (Peak G ) (a), delta change in glucose levels (ΔG) (b), area under the curve for glucose (G AUC ) (c), and area under the curve for insulin (I AUC ) (d). Multivariable analyses described in Table 3 represent the statistical differences between individual categories. (Fig. 3) . This observation suggests that the combination of SO and PCOS, both independently and in combination, increases the risk for disturbances in glucose metabolism. This is extremely important because decreased glucose effectiveness similarly to a delayed insulin release has been associated with the development of IGT or T2DM in various populations [30, 31] . Thus, the degree of obesity, altered SgI o , and delayed insulin peak in response to a glucose load may be in part responsible for the increase in Peak G , ΔG, and G AUC seen in SO-PCOS subjects. Our study has several strengths. This is the largest cohort of adolescents and young adults with PCOS and controls over a wide BMI range that has been assessed for abnormalities in glucose metabolism using an OGTT. Although our program represents a single center, our population is ethnically diverse and demonstrated that ethnicity did not impact the indices of glucose and insulin dynamics.
Limitations of our study include the use of OGTT-derived indices as a surrogate method of determining glucose and insulin dynamics rather than an intravenous glucose tolerance test. Although these indices have been validated against complex tests by cross-sectional analysis [32] , there is concern that they may perform relatively poorly in determining subtle changes in insulin sensitivity and/or secretion.
Other studies have suggested that abnormal oral glucose tolerance and/or diabetes is present in 30-40% of PCOS women and adolescents as well [11, 22, [33] [34] [35] [36] . In our study, only 1 subject was found to have diabetes, 3% of PCOS had IFG, and 15% had IGT. The lower rate of these disorders in our population may be related to heterogeneity of populations, age, and the PCOS diagnostic criteria used, or cohort size. Thus, if the differences between the prevalence of IGT and/or diabetes between PCOS subjects and controls are mainly dependent on the degree of obesity, our cohort is the first to demonstrate the usefulness of determining the prevalence of IFG, abnormal OGTT, and diabetes compared to age-comparable controls. The choice of utilizing an OGTT to evaluate glucose and insulin dynamics in this cohort has given us the unique opportunity to gather clinically important information and a better understanding about the underlying physiology beyond the fasting state.
Conclusions
This study sought to delineate the intricate relationship between obesity and PCOS adolescents across a wide BMI spectrum. Whereas abnormal IS and insulin secretion were not identified in NW-PCOS subjects; alterations in glucose response to an OGTT decreased glucose effectiveness and delayed insulin secretion was observed in SO-PCOS subjects. This observation underscores the complex effects of BMI and PCOS on metabolic abnormalities. Thus, in a large cohort of ethnically diverse adolescents and young adults with PCOS who span a wide range of BMIs, we have identified that those with PCOS and who are SO are a unique group with increased risk of developing abnormalities in glucose metabolism. Future longitudinal studies are needed to better elucidate the long-term implications and potential preventive measures that may be implemented in this high-risk group.
